IDEAYA, AstraZeneca launch global IDE849-Imfinzi lung cancer trial

An announcement from IDEAYA Biosciences ( (IDYA) ) is now available.

On April 8, 2026, IDEAYA Biosciences entered a clinical collaboration with AstraZeneca to test IDE849, its investigational DLL3 TOP1 antibody-drug conjugate, in combination with AstraZeneca’s PD-L1 inhibitor Imfinzi in extensive-stage small cell lung cancer. IDEAYA will sponsor the study while AstraZeneca supplies Imfinzi, reinforcing IDEAYA’s efforts to expand treatment options in difficult-to-treat solid tumors.

The collaboration is integrated into IDEAYA’s ongoing multi-site global Phase 1 trial of IDE849 across DLL3 upregulated solid tumors, including SCLC, neuroendocrine carcinomas, neuroendocrine tumors, and melanoma, with enrollment spanning North America, Europe, Australia, South America, and Asia. Because DLL3 is highly expressed in several solid tumors but shows limited extracellular expression in normal tissues, this program targets a promising biomarker in areas of significant unmet medical need, potentially strengthening IDEAYA’s position in targeted oncology.

The most recent analyst rating on (IDYA) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.

Spark’s Take on IDYA Stock

According to Spark, TipRanks’ AI Analyst, IDYA is a Neutral.

The score is driven primarily by mixed financial performance—strong balance sheet strength offset by continued losses and weak cash flow quality. Technicals are a clear headwind with bearish momentum and the stock trading below key moving averages, while corporate updates provide some support via funded clinical progress despite the GSK collaboration termination. Valuation is difficult to assess due to negative earnings and no dividend.

To see Spark’s full report on IDYA stock, click here.

More about IDEAYA Biosciences

IDEAYA Biosciences, Inc. is a biotechnology company developing targeted oncology therapies, with a focus on investigational antibody-drug conjugates and precision medicines for solid tumors. Its pipeline includes IDE849, a potential first-in-class DLL3 TOP1 antibody-drug conjugate aimed at treating DLL3 upregulated solid tumor indications such as small cell lung cancer, neuroendocrine carcinomas, neuroendocrine tumors, and melanoma.

Average Trading Volume: 910,875

Technical Sentiment Signal: Buy

Current Market Cap: $2.72B

See more insights into IDYA stock on TipRanks’ Stock Analysis page.